KaloBios, the relatively unknown penny stock pharma company, which was on the verge of bankruptcy, hit the headlines after controversial figure Martin Shkreli took a large stake in the company and became its CEO, is falling apart as managers flee the sinking ship. Prior to Shkreli’s investment, at the beginning of December, KaloBios was running out of cash fast and had planned to shut down before the end of the year. However, Shkreli rode to the rescue of KaloBios with a $8.2 million cash infusion enabling the company to fund the $2 million acquisition of a benznidazole program for treating Chagas disease…
KaloBios (KBIO) Crumbles: Shkreli Arrested & Fired, Delisted And Board Members Quit
Sign up now and get our in-depth FREE e-books on famous investors like Klarman, Dalio, Schloss, Munger Rupert is a committed value investor and regularly writes and invests following the principles set out by Benjamin Graham. He is the editor and co-owner of Hidden Value Stocks, a quarterly investment newsletter aimed at institutional investors. Rupert owns shares in Berkshire Hathaway. Rupert holds qualifications from the Chartered Institute For Securities & Investment and the CFA Society of the UK. Rupert covers everything value investing for ValueWalk